<DOC>
	<DOCNO>NCT00245128</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase II trial study side effect imatinib mesylate well work treat patient myelofibrosis .</brief_summary>
	<brief_title>Imatinib Mesylate Treating Patients With Myelofibrosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety , efficacy , tolerability imatinib mesylate patient myelofibrosis myeloid metaplasia . - Determine 3- , 6- , 12-month major minor erythroid response rate patient treated drug . Secondary - Determine reduction marrow fibrosis patient treat drug . - Determine decrease spleen size patient treat drug . OUTLINE : This multicenter , open-label , nonrandomized , pilot study . Patients receive oral imatinib mesylate daily 1 year absence disease progression unacceptable toxicity . Patients experience minor erythroid response 50 % reduction spleen size 6 month treatment remove study . Patients experience clinical benefit ( e.g. , ongoing erythroid response ) 1 year treatment may continue treatment imatinib mesylate discretion principal investigator . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis myelofibrosis myeloid metaplasia ( MMM ) , define follow : Leukoerythroblastic blood picture Fibrosis involve &gt; 1/3 sectional area bone marrow biopsy Splenomegaly ( unless patient undergone prior splenectomy ) Philadelphia chromosome negative No myelodysplastic syndrome No systemic disorder associate marrow fibrosis Red blood cell transfusion dependent , define 1 following : Patient require ≥ 2 unit red blood cell every 4 week within past 8 week Hemoglobin ≤ 8 g/dL ≥ 3 occasion ( ≥ 2 week apart ) past 8 week No evidence disease transformation acute myelogenous leukemia , define &gt; 20 % blast bone marrow and/or peripheral blood PATIENT CHARACTERISTICS : Performance status ECOG 03 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 50,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2 time ULN ( unless due extramedullary hematopoiesis liver ) Renal Creatinine ≤ 1.5 time ULN Cardiovascular No New York Heart Association grade IIIIV heart disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier method contraception 3 month completion study treatment No serious , uncontrolled medical condition No patient consider potentially unreliable history noncompliance medical regimen PRIOR CONCURRENT THERAPY : Biologic therapy More 2 week since prior interferon alfa Chemotherapy No concurrent chemotherapy except hydroxyurea control elevate blood count Endocrine therapy More 4 week since prior corticosteroid , danazol , androgen MMM Other More 4 week since prior treatment MMM No concurrent experimental drug therapy MMM</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>essential thrombocythemia</keyword>
</DOC>